Multicomponent Meningococcal group B vaccine (recombinant, adsorbed)
Consumer Medicine Information
What is in this leaflet
Read all of this leaflet carefully before you are vaccinated.
This leaflet answers some common questions about BEXSERO®.
It does not contain all the available information. It does not take the place of talking
to your doctor or pharmacist.
The information in this leaflet was last updated on the date listed on the final page.
More recent information on the medicine may be available.
You should ensure that you speak to your pharmacist or doctor to obtain the most up-to-date
information on the medicine. You can also download the most up-to-date leaflet from
Those updates may contain important information about the medicine and its use of
which you should be aware.
All medicines, including vaccines, have risks and benefits. Your doctor has weighed
the risks of you or your child having BEXSERO against the benefits they expect it
will have for you.
If you have any concerns about this medicine, ask your doctor, nurse or pharmacist.
Keep this leaflet.
You may need to read it again.
What BEXSERO is used for
BEXSERO is a meningococcal group B vaccine.
BEXSERO is given to individuals from 2 months of age and older to help protect against
disease caused by bacteria called Neisseria meningitidis group B. These bacteria can
cause serious, and sometimes life-threatening, infections such as meningitis (inflammation
of the covering of the brain and spinal cord) and sepsis (blood poisoning).
The vaccine works by specifically stimulating the body's natural defense system of
the vaccinated person. This results in protection against this disease.
The use of this vaccine should be in accordance with the official recommendations.
Please note that BEXSERO can only protect you or your child from meningitis caused
by Neisseria meningitidis group B.
BEXSERO is not expected to provide protection against all circulating meningococcal
group B types.
How BEXSERO works
BEXSERO works by causing you or your child's body to produce its own protection (or
antibodies), against the meningococcal group B bacteria. Your or your child's body
usually takes a couple of weeks after vaccination to develop protection against Neisseria
meningitidis group B.
If a vaccinated person comes into contact with Neisseria meningitidis group B, the
body is usually able to destroy it. However, as with all vaccines, 100% protection
cannot be guaranteed.
As with all vaccines, occasionally, individuals may react unfavourably to the vaccine.
The chance of a severe reaction from BEXSERO is very small, but the risks from not
being vaccinated against meningococcal disease may be very serious.
BEXSERO should not be given to a person who has:
allergy (hypersensitivity) to the active substances or any of the other ingredients
of BEXSERO listed at the end of this leaflet. Signs of an allergic reaction may include:
shortness of breath, wheezing or difficulty breathing,
swelling of the face, lips, tongue or other parts of the body,
skin rash, itching or hives
In addition, BEXSERO should not be administered if:
the expiry date printed on the pack has passed
the packaging is torn or shows signs of tampering.
If you are not sure whether you or your child should have BEXSERO, talk to your doctor,
nurse or pharmacist.
Before you or your child receives BEXSERO
Tell your doctor or pharmacist if you have/your child has allergies to:
active substances or any of the other ingredients of BEXSERO
the antibiotic kanamycin. If present, the kanamycin level in the vaccine is low
latex. Although no natural rubber latex is detected in the syringe tip cap, the safe
use of BEXSERO in latex-sensitive individuals has not been established.
Tell your doctor if in the past you or your child have/has reacted to any vaccination
with any of the following:
severe allergic reaction
swelling of the throat
Tell your doctor if you have/your child has a severe infection with a high temperature.
If this is the case, then vaccination will be postponed. The presence of a minor infection,
such as a cold, should not require postponement of the vaccination, but talk to your
If your child was born prematurely (before or at 28 weeks of pregnancy), particularly
if they had breathing difficulties, please tell your doctor. Stopping breathing or
irregular breathing for a short time may be more common in the first three days following
vaccination in these babies and they may need special monitoring.
Fainting, feeling faint or other stress-related reactions can occur as a response
to any needle injection.
Tell your doctor or nurse if you have experienced this kind of reaction previously
Tell your doctor if you or your child have or have had any medical conditions especially
an immune deficiency condition. Little is known about the effectiveness of BEXSERO
when administered to individuals with weakened immunity due to the use of immunosuppressive
medications, or HIV infection, or hereditary defects of the body's natural defence
system. It is possible the effectiveness of BEXSERO could be reduced in such individuals.
The safety and efficacy of BEXSERO in adults above 50 years of age have not been established.
There are limited data on the use in patients with chronic medical conditions.
Tell your doctor if you are pregnant or intend to become pregnant soon.
Your doctor will discuss the possible risks and benefits of receiving BEXSERO vaccine
during pregnancy. Your doctor may still recommend that you receive BEXSERO if you
are at risk of exposure to meningococcal infection.
Tell your doctor if you are breastfeeding.
Your doctor will discuss the possible risks and benefits of receiving BEXSERO vaccine
Tell your doctor or pharmacist if you or your child are taking, or have recently taken,
any other medicines, including any that you buy without a prescription from your pharmacy,
supermarket or health food shop.
Having other vaccines
Tell your doctor if you or your child has had any vaccines recently.
BEXSERO may be given at the same time as other vaccinations.
When given at the same time as other vaccines, BEXSERO must be administered at a separate
injection site. BEXSERO can be given at the same time as any of the following vaccines
diphtheria, tetanus, whooping cough (pertussis), Haemophilus influenzae type b, polio,
hepatitis B, pneumococcus, measles, mumps, rubella, chickenpox and meningococcus C.
Your doctor may ask you to give your child medicines that lower fever after BEXSERO
has been given. This will help to reduce some of the side effects of BEXSERO.
Your doctor or pharmacist may have more information on medicines and vaccines that
require special precautions or should be avoided during vaccination with BEXSERO.
How BEXSERO is given
How it is given
BEXSERO is given as an injection, usually into your or your child's arm or leg muscle.
It is important to follow the instructions from your doctor or nurse so that you or
your child completes the course of injections.
If you have any concerns about how this vaccine is to be given, talk to your doctor,
nurse or pharmacist.
How much is given
The dose is 0.5 mL given by injection.
You or your child may be given more than one single dose of BEXSERO. Please talk to
your doctor, nurse or pharmacist to get more information.
You should keep a record of your/ your child's vaccinations.
Tell your doctor or pharmacist as soon as possible if you or your child does not feel
well after having BEXSERO.
Like all vaccines, BEXSERO can cause side effects, although not everybody gets them.
When BEXSERO is given to you or your child, the most common side effects that you
may get are:
pain at the injection site, redness at the injection site, swelling of skin at the
injection site, hardness of skin at the injection site, generally feeling unwell,
headache, fever (38°C or higher) and feeling irritable.
The following side effects may occur after receiving this vaccine:
Infants, toddlers and children (up to 10 years of age)
fever (38°C or higher), loss of appetite, tenderness or discomfort to touch at the
injection site (including severe tenderness at injection site resulting in crying
when injected limb was moved), redness of skin at the injection site, skin rash in
toddlers (uncommon after booster), hardness of skin at the injection site, swelling
of skin at the injection site, sleepiness, feeling irritable, unusual crying, vomiting
(uncommon after booster), diarrhea, headache, painful joints.
skin rash in infants and children aged 2 to 10 years, fever (39.5°C or higher).
The incidence of fever may be decreased by the use of paracetamol. Before you or your
child receives vaccination, ask your doctor about the risks of fever and how to treat
it, including what to do if fever does not respond to initial treatment.
high fever (40°C or higher), seizures (including febrile seizures due to fever), dry
skin, paleness (rare after booster).
Kawasaki disease which may include symptoms such as fever that lasts for more than
five days, associated with a rash on the trunk of the body, and sometimes followed
by a peeling of the skin on the hands and fingers, swollen glands in the neck, red
eyes, lips, throat and tongue.
Itchy rash, skin rash.
Adolescents (from 11 years of age) and Adults
pain at the injection site (including severe pain at injection site resulting in inability
to perform normal daily activity), redness of skin at the injection site, swelling
of skin at the injection site, hardness of skin at the injection site, painful muscles
and joints, nausea, generally feeling unwell, headache.
Other side effects reported during marketed use include:
allergic reactions that may include severe swelling of the lips, mouth, throat (which
may cause difficulty in swallowing), difficulty breathing with wheezing or coughing,
rash, loss of consciousness and very low blood pressure
collapse (sudden onset of muscle floppiness), less responsive than usual or lack of
awareness, and paleness or bluish skin discolouration in young children
feeling faint or fainting
fever (adolescents from 11 years of age and adults), injection site reactions like
extensive swelling of the vaccinated limb, blisters at or around the injection site
and hard lump at the injection site (which may persist for more than one month)
If any of the side effects gets serious, or if you notice any side effects not listed
in this leaflet, please tell your doctor.
No studies on the effects on the ability to drive and use machines have been performed.
However, some of the side effects mentioned under section Side Effects may temporarily
affect the ability to drive or use machines.
Ask your doctor or pharmacist to answer any questions you may have.
Keep BEXSERO away from light.
Keep it in the refrigerator (between 2°C and 8°C).
Do not freeze BEXSERO.
Do not use BEXSERO after the expiry date which is stated on the carton.
Keep out of the reach and sight of children.
Medicines should not be disposed of in wastewater or household waste. Ask your doctor
how to dispose of medicines that are out of date or no longer required. These measures
will help to protect the environment.
What it looks like
BEXSERO is a white, opalescent liquid suspension for injection, supplied in a pre-filled
syringe providing 1 dose of 0.5 ml.
The active ingredients are:
50 micrograms of Neisseria meningitidis Group B Neisseria Heparin Binding Antigen
fusion protein (rbe); 50 micrograms of Neisseria meningitidis Group B Neisseria Adhesin
A protein (rbe);
50 micrograms of Neisseria meningitidis Group B Factor H Binding Protein fusion protein
(rbe); 25 micrograms of Outer Membrane Vesicles from Neisseria meningitidis group
B strain NZ98/254.
Antigens are adsorbed on aluminium hydroxide (0.5 mg aluminium).
The other ingredients are: sodium chloride, histidine, sucrose and water for injections.
BEXSERO is supplied in packs of 1 or 10 syringes, supplied with or without needles.
Not all pack sizes may be marketed.
BEXSERO does not contain lactose, gluten, thiomersal (organic mercurials), tartrazine
or any other azodyes.
GlaxoSmithKline Australia Pty Ltd
Level 4, 436 Johnston Street
Abbotsford, Victoria, 3067
Australian Registration Numbers:
BEXSERO pre-filled syringe without needle (AUST R 190718)
BEXSERO pre-filled syringe with needle (AUST R 190719)
This leaflet was prepared 4 July 2017.
Bexsero® is a registered trademark of the GSK group of companies